drugs for obesity are a massive market, says mizuho's jared holz
Published 1 year ago • 2.1K plays • Length 5:47Download video MP4
Download video MP3
Similar videos
-
4:08
weight loss drug market is just beginning to take off, says mizuho's jared holz
-
7:35
eli lilly's zepbound single-dose vials will expand access to more patients: mizuho's jared holz
-
5:05
amgen has 'a lot to prove' in the weight-loss drug category, says mizuho's jared holz
-
4:25
people are 'scratching and clawing' for negative narrative around obesity drugs: mizuho's jared holz
-
6:57
mizuho's jared holz on drug price negotiations: more difficult for industry to get better medicines
-
5:13
obesity drug enthusiasm can continue in 2024: mizuho's jared holz
-
5:12
structure therapeutics is a 'no-brainer takeout' target, says mizuho's jared holz
-
6:00
mizuho's jared holz reacts to jpmorgan's huge obesity drug call
-
3:53
eli lilly's alzheimer drug is 'a nice additional therapy', says mizuho's jared holz
-
5:53
eli lilly and novo nordisk will remain leaders in the weight-loss drug market: mizuho's jared holz
-
3:43
mizuho's holz on weight loss drugs: lilly and novo nordisk are in excellent shape fundamentally
-
5:47
zealand's obesity drug shouldn't disrupt novo nordisk-eli lilly leadership: mizuho's jared holz
-
5:57
new weight loss drugs will help tackle america's obesity epidemic, says dr. scott gottlieb
-
6:08
eli lilly's dtc obesity drug push 'not necessarily an industry game changer': mizuho's jared holz
-
5:52
expectations for pfizer have been low, says mizuho's jared holz on weight-loss pill setback
-
5:26
obesity drug supply-demand imbalance is working in novo nordisk's favor: mizuho's jared holz
-
3:40
eli lilly's obesity drug will be a tailwind for the stock, says bmo's evan seigerman
-
3:14
election noise may make pharmaceutical stocks 'untenable' for investors, says mizuho's jared holz
-
7:05
upside for emergent bio if they can get mpox vaccine rollout right, says mizuho's jared holz